Barricade Therapeutics
Business Services · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1120 South Fwy Ste 103, Fort Worth, Texa...Revenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Barricade Therapeutics
Barricade Therapeutics is a clinical-stage oncology company dedicated to developing first-in-class oral therapies for genetically driven cancers, particularly colorectal cancer. The company is advancing BT-1501, an investigational oral therapy designed to target the biological drivers of colorectal cancer progression. With a focus on precision and patient tolerability, Barricade aims to address significant unmet needs in the oncology market, which is characterized by high incidence and limited treatment options. Backed by substantial funding and independent validation from leading institutions, Barricade is positioned for meaningful clinical and commercial impact.Explore more
Barricade Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Barricade Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Barricade Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Barricade Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Barricade Therapeutics
Check out if Barricade Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Barricade Therapeutics has new funding data
Earning: See what the market has to say on Barricade Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Barricade Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Barricade Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Barricade Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Barricade Therapeutics
Compare insights from companies similar to Barricade Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Barricade Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Barricade Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Barricade Therapeutics.
Barricade Therapeutics financials insights
Gather financial insights about Barricade Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$62K
Barricade Therapeutics Tech Stack
A closer look at the technologies used by Barricade Therapeutics
Barricade Therapeutics News & Media
Fort Worth-based Barricade Therapeutics secures $14 million CPRIT grant to advance ...
FORT WORTH, TX (Nov. 22, 2024) – Barricade Therapeutics, Corp., a bio-pharmaceutical company pioneering solutions for colorectal cancer, has received aTASIN Selectively Targets Colon Cancer Cells Expressing Truncated APC
HOUSTON--(BUSINESS WIRE)--A study conducted at the Departments of Biochemistry (Jef De Brabander) and Cell Biology (Jerry Shay), University of Texas Southwestern Medical Center, Dallas, TX has demonstrated that TASIN (Truncated APC Selective INhibitor), a recently identified small molecule, selectively kills colorectal cancer cells (CRC) by inducing endoplasmic reticulum (ER) stress which leads to activation of the pro-apoptotic JNK pathway and PARP cleavage. The ER is a central organelle involNew Preclinical Data for THIO in BRAF-Mutant Mouse Melanoma Models
HOUSTON--(BUSINESS WIRE)--A study conducted at The Wistar Institute in collaboration with The University of Texas Southwestern Medical Center has demonstrated the efficacy of targeting aberrantly active telomerase to treat therapy-resistant melanoma. The research was published in the journal Clinical Cancer Research (http://clincancerres.aacrjournals.org/content/early/2018/03/21/1078-0432.CCR-17-2773). A hallmark of several cancer types, including melanoma, is increased telomerase activation. T
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Barricade Therapeutics
Sign Up For FreeTo access detailed company insights
Barricade Therapeutics is a clinical-stage oncology company dedicated to developing first-in-class oral therapies for genetically driven cancers, particularly colorectal cancer. The company is advancing BT-1501, an investigational oral therapy designed to target the biological drivers of colorectal cancer progression. With a focus on precision and... Read More
